A group of researchers discovered a promising new approach to treating leukemia by disarming a gene that is responsible for tumor progression.
Vemurafenib, a BRAF inhibitor that has been approved as a treatment for advanced melanomas, has also proved successful in treating hairy cell leukemia.
Linear dose-response relationship for acute lymphoblastic leukemia and acute myeloid leukemia has been observed.
Targeted treatments for acute promyelocytic leukemia cause a cascade of molecular events that lead to cellular senescence and recovery. This action model could be activated in other types of cancers.
Scientists have discovered a genetic signature that implicates a key mechanism in the immune system as a driving force for a type of childhood leukemia.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|